Avisa Diagnostics Appoints G. Michael Landis as Chief Financial Officer
- Financial executive with strong public company experience joins growing Avisa team
Santa Fe, NM, June 22, 2021. Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, is pleased to announce that G. Michael Landis has joined Avisa as Chief Financial Officer, effective immediately. Matthew Culler, who has led the company through the merger with Fogchain Corp and the listing on the Canadian Securities Exchange, will remain with Avisa as an advisor during a transition period.
G. Michael Landis has over 25 years of finance and accounting experience in a variety of industries and has strong public company expertise, including the areas of capital market transactions, investor relations and financial reporting.
Prior to joining Avisa, Mr. Landis served at Lannett Company, Inc., a publicly traded generic pharmaceutical company, in various financial leadership roles, most recently as Principal Accounting Officer and Treasurer. While there, he led acquisitions and related financing activities and was a member of the executive team that successfully completed a $1.2 billion acquisition. Prior to joining Lannett, he worked in senior level finance and controllership positions at Akrion, Inc. and AlliedBarton Security Services, LLC; at both of these companies, he was actively involved in the Initial Public Offering (IPO). He also served as Assistant Global Controller at Quaker Chemical Corporation. Earlier in his career, Mr. Landis worked at the international accounting firm, Deloitte & Touche LLP. He earned a Bachelor of Arts degree in accounting from Franklin & Marshall College in Lancaster, PA and is a Certified Public Accountant (CPA).
David S. Joseph, President and Chief Executive Officer of Avisa, said: “We are pleased to welcome Mike to Avisa. He has the financial acumen and reporting expertise that we need now that we are a publicly listed company. With his wide-ranging experience and knowledge, he will be an invaluable member of the leadership team as Avisa grows. I look forward to working with him.”
Mr. Joseph continued: “I would also like to take this opportunity to warmly thank Matt Culler for his contributions to Avisa. Matt has been an important member of the team helping Avisa to move to the next phase of our growth. We are delighted he has agreed to stay longer to ensure a smooth transition.”
G. Michael Landis, Chief Financial Officer of Avisa, said: “I am excited to join Avisa at this important stage of the company’s development and to have the opportunity to contribute my public company expertise. It is highly gratifying to be part of a team that is working so hard to help doctors and their patients by advancing an important technology to help diagnose and monitor patients with severe lung disease quickly that will provide physicians with actionable data to guide treatment.”
About Avisa Diagnostics Inc.
Avisa (CSE-AVBT) is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The Company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year. For further information, visit http://avisadx.com/ and follow us on LinkedIn and Twitter.
Avisa Diagnostics Inc.
Investors and Media Contacts
MC Services AG
Laurie Doyle, Raimund Gabriel
E-mail: [email protected]
Europe: +49 89-210 2280
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes, but is not limited to, statements about the business plans and expectations of the Company and expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward- looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Resulting Issuer. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: (i) changes in general economic, business and political conditions, including changes in the financial markets, changes in applicable laws and regulations both locally and in foreign jurisdictions; (ii) compliance with extensive government regulation and the costs associated with compliance; (iii) the risks and uncertainties associated with foreign markets; and (iv) risks associated with the COVID-19 pandemic. This forward-looking information may be affected by risks and uncertainties in the business of the Resulting Issuer and market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. The Company does not intend, nor assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.